Skip to main content
Premium Trial:

Request an Annual Quote

Duke Licenses NPM1 from Trovagene for AML Research, Testing

NEW YORK (GenomeWeb News) – Trovagene today announced it has granted Duke University and Duke University Health Systems a non-exclusive license covering the use of the nucleophosmin protein (NPM1).

The agreement allows Duke to incorporate NPM1 into research and clinical testing services for acute myelogenous leukemia. The terms of the deal includes upfront payments and royalties. Further details were not disclosed.

Trovagene holds the exclusive worldwide license to the patent around NPM1. Duke is the latest licensee of the technology. Last week, Trovagene said that Genoptix licensed rights to use NPM1, and others that have sublicensed the protein include Quest Diagnostics, Laboratory Corporation of America, and Münchner Leukamielabor in Germany.

Trovagene also has co-licensing deals with Asuragen and Ipsogen, part of Qiagen, to manufacture and sell NPM1 mutation kits.

The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.